No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATXS240719P10000
- 0.25
- -0.65-72.22%
15min DelayClose Jul 11 15:58 ET
0.30High0.25Low
0.30Open0.90Pre Close8 Volume323 Open Interest10.00Strike Price205.00Turnover112.42%IV13.33%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.2141Delta0.1544Gamma45.00Leverage Ratio-0.0340Theta-0.0006Rho-9.63Eff Leverage0.0049Vega
Intraday
- 5D
- Daily
News
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer: The Astria Therapeutics (ATXS.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $29.00 to $25.00.
Oppenheimer: The Astria Therapeutics (ATXS.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $29.00 to $25.00.